Cargando…

Prognostic Role of KRAS G12C Mutation in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

KRAS G12C mutation (mKRAS G12C) is the most frequent KRAS point mutation in non-small cell lung cancer (NSCLC) and has been proven to be a predictive biomarker for direct KRAS G12C inhibitors in advanced solid cancers. We sought to determine the prognostic significance of mKRAS G12C in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wankhede, Durgesh, Bontoux, Christophe, Grover, Sandeep, Hofman, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572143/ https://www.ncbi.nlm.nih.gov/pubmed/37835787 http://dx.doi.org/10.3390/diagnostics13193043

Ejemplares similares

Circulating Tumor Cells as a Predictive Biomarker in Resectable Lung Cancer: A Systematic Review and Meta-Analysis
por: Wankhede, Durgesh, et al.
Publicado: (2022)

The prognostic value of TMB in early-stage non-small cell lung cancer: a systematic review and meta-analysis
por: Wankhede, Durgesh, et al.
Publicado: (2023)

Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis
por: Wankhede, Durgesh, et al.
Publicado: (2023)

Morphological and Molecular Characterization of KRAS G12C-Mutated Lung Adenocarcinomas
por: Pirlog, Radu, et al.
Publicado: (2022)

KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
por: Park, Sehhoon, et al.
Publicado: (2017)

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients
por: Liu, Si-Yang, et al.
Publicado: (2020)

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
por: Vaclova, Tereza, et al.
Publicado: (2022)

Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
por: Qunaj, Lindor, et al.
Publicado: (2023)

Is Laterality Prognostic in Resected KRAS-Mutated Colorectal Liver Metastases? A Systematic Review and Meta-Analysis
por: Belias, Michail, et al.
Publicado: (2022)

Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation
por: Wu, Markus Y., et al.
Publicado: (2021)

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
por: Ricciuti, Biagio, et al.
Publicado: (2022)

Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
por: Lee, Arnold
Publicado: (2022)

Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner
por: Bontoux, Christophe, et al.
Publicado: (2022)

Resistance to KRAS(G12C) Inhibitors in Non-Small Cell Lung Cancer
por: Blaquier, Juan Bautista, et al.
Publicado: (2021)

Correction to: Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
por: Lee, Arnold
Publicado: (2022)

Targeting KRAS G12C mutations in colorectal cancer
por: Zhao, Ming-He, et al.
Publicado: (2022)

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases
por: Renaud, Stéphane, et al.
Publicado: (2015)

Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
por: Noordhof, Anneloes L., et al.
Publicado: (2023)

The Prevalence and Concurrent Pathogenic Mutations of KRAS(G12C) in Northeast Chinese Non-small-cell Lung Cancer Patients
por: Liu, Yan, et al.
Publicado: (2021)

KRAS (G12C) mutation‐induced TOPK overexpression contributes to tumour progression in non‐small cell lung cancer
por: Cai, Chang, et al.
Publicado: (2023)

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C
por: Notario, Lucía, et al.
Publicado: (2023)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

Overcoming Resistance to Drugs Targeting KRAS(G12C) Mutation
por: Jiao, Delong, et al.
Publicado: (2020)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

The Research Progress of Direct KRAS G12C Mutation Inhibitors
por: Yang, Ai, et al.
Publicado: (2021)

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
por: Bournet, Barbara, et al.
Publicado: (2016)

KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients
por: Fu, Xin-Hui, et al.
Publicado: (2019)

KRAS p.G12C Mutation in Metastatic Colorectal Cancer: Prognostic Implications and Advancements in Targeted Therapies
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer
por: Araujo, Luiz Henrique, et al.
Publicado: (2021)

Intracranial responses with selective KRAS-G12C inhibitors in non-small cell lung cancer
por: Lu, Kevin, et al.
Publicado: (2023)

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

Sotorasib in KRAS(G12C) mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
por: Olivier, Timothée, et al.
Publicado: (2022)

Corrigendum: The Research Progress of Direct KRAS G12C Mutation Inhibitors
por: Yang, Ai, et al.
Publicado: (2022)

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2023)

Detection of KRAS G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer
por: Michaelidou, Kleita, et al.
Publicado: (2020)

Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
por: Chen, Chih-Chieh, et al.
Publicado: (2013)

Practical Guidance for the Management of Adverse Events in Patients with KRAS(G12C)-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib
por: Zhang, Jun, et al.
Publicado: (2023)

Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report
por: Iska, Sindu, et al.
Publicado: (2023)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jv5sbq6flt30hik99gsqe7t3gr